Valuation: Valneva SE Pref.

Market Cap 421M 485M 394M 361M 680M 46.16B 690M 4.61B 1.81B 23.14B 1.82B 1.78B 76.9B P/E 2026 *
-6.05x
P/E 2027 * 5.31x
Enterprise Value 549M 633M 514M 470M 887M 60.19B 900M 6.02B 2.36B 30.17B 2.38B 2.32B 100B EV / Sales 2026 *
3.62x
EV / Sales 2027 * 1.64x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Valneva SE Pref.

Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 28/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 19/12/2023
Director/Board Member 75 06/03/2013
Chairman 65 19/12/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 489M
+0.93%-1.43%+1.61%+14.93% 48.57B
+0.26%+9.34%+415.26%+533.80% 41.95B
-1.53%-6.11%+26.37%+7.15% 38.85B
+0.69%+0.79%+7.35%+63.05% 37.24B
+2.47%+8.33%+15.16%+48.37% 30.67B
-0.47%+0.01%+34.08%+126.09% 16.41B
+2.31%-0.87% - - 16.1B
+0.29%+1.81%+4.92%+18.60% 13.97B
-1.43%-9.55%-2.90%-36.38% 12.62B
Average +0.35%-0.30%+62.73%+96.95% 28.48B
Weighted average by Cap. +0.44%+0.39%+82.62%+121.09%

Financials

2026 *2027 *
Net sales 152M 175M 142M 130M 245M 16.64B 249M 1.66B 652M 8.34B 657M 642M 27.72B 294M 339M 275M 252M 475M 32.23B 482M 3.22B 1.26B 16.15B 1.27B 1.24B 53.68B
Net income -66.01M -76.06M -61.8M -56.54M -107M -7.23B -108M -723M -284M -3.63B -286M -279M -12.05B 77.68M 89.51M 72.73M 66.54M 125M 8.51B 127M 851M 334M 4.27B 336M 329M 14.18B
Net Debt 128M 147M 120M 110M 207M 14.03B 210M 1.4B 550M 7.03B 554M 542M 23.37B 60.02M 69.15M 56.19M 51.41M 96.91M 6.58B 98.35M 658M 258M 3.3B 260M 254M 10.96B
Logo Valneva SE Pref.
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.221EUR
Average target price
5.233EUR
Spread / Average Target
+135.63%

Quarterly revenue - Rate of surprise